The performance of non-NAAT point-of-care (POC) tests and rapid NAAT tests for chlamydia and gonorrhoea infections. An assessment of currently available assays

Sexually Transmitted Infections

Volumn 91, Issue 8, 2015, Pages 539-544

  Brook, Gary ^a  

^a CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COST BENEFIT ANALYSIS; GONORRHEA; HOSPITAL INFORMATION SYSTEM; HUMAN; ISOLATION AND PURIFICATION; NEISSERIA GONORRHOEAE; NUCLEIC ACID AMPLIFICATION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM;

CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COST-BENEFIT ANALYSIS; GONORRHEA; GREAT BRITAIN; HUMANS; NEISSERIA GONORRHOEAE; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POINT-OF-CARE SYSTEMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84930599503     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sextrans-2014-051997     Document Type: Article

References (30)

1. Huppert JS, Hesse EA, Gaydos CA. What's the point? How point-of-care STI tests can impact infected patients. Point Care 2010; 9: 36-46.
2. Watchirs Smith LA, Hillman R, Ward J, et al. Point-of-care tests for the diagnosis of Neisseria gonorrhoeae infection: A systematic review of operational and performance characteristics. Sex Transm Infect 2013; 89: 320-6.
3. Huang W, Gaydos CA, Barnes MR, et al. Comparative effectiveness of a rapid point-of-care test for detection of Chlamydia trachomatis among women in a clinical setting. Sex Transm Infect 2013; 89: 108-14.
4. Jain A, Ison CA. Chlamydia point-of-care testing: Where are we now? Sex Transm Infect 2013; 89: 88-9.
5. Miners A. Is nucleic acid amplification point-of-care testing for chlamydia and gonorrhoea cost-effective? Sex Transm Infect 2014; 90: 82.
6. Turner KME, Round J, Horner P, et al. An early evaluation of clinical and economic costs and benefits of implementing point of care NAAT tests for Chlamydia trachomatis and Neisseria gonorrhoea in genitourinary medicine clinics in England. Sex Transm Infect 2014; 90: 104-11.
7. Hislop J, Quayyum Z, Flett G, et al. Systematic review of the clinical effectiveness and cost-effectiveness of rapid point-of-care tests for the detection of genital chlamydia infection in women and men. Health Technol Assess 2010; 14: 1-97.
8. Benzaken AS, Galban EG, Antunes W, et al. Diagnosis of gonococcal infection in high risk women using a rapid test. Sex Transm Infect 2006; 82(Suppl V): V26-8.
9. Saison F, Mahilum-Tapay L, Michel CE, et al. Prevalence of Chlamydia trachomatis infection among low- and high-risk Filipino Women and performance of Chlamydia Rapid Tests in resource-limited settings. J Clin Microbiol 2007; 45: 4011-17.
10. Yin Y-P, Peeling RW, Chen X-S, et al. Clinic-based evaluation of Clearview Chlamydia MF for detection of Chlamydia trachomatis in vaginal and cervical specimens from women at high risk in China. Sex Transm Infect 2006; 82(Suppl V): V33-7.
11. Hurly DS, Buhrer-Skinner M, Badman SG, et al. Field evaluation of the CRT and ACON chlamydia point-of-care tests in a tropical, low-resource setting. Sex Transm Infect 2014; 90: 179-84.
12. Michel C-EC, Saison FG, Joshi H, et al. Pitfalls of internet-accessible diagnostic tests: Inadequate performance of a CE-marked Chlamydia test for home use. Sex Transm Infect 2009; 85: 187-9.
13. van Dommelen L, van Tiel FH, Ouburg S, et al. Alarmingly poor performance in Chlamydia trachomatis point-of-care testing. Sex Transm Infect 2010; 86: 355-9.
14. Goldenberg SD, Finn J, Sedudzi E, et al. Performance of the GeneXpert CT/NG assay compared to that of the Aptima AC2 assay for detection of rectal Chlamydia trachomatis and Neisseria gonorrhoeae by use of residual Aptima samples. J Clin Microbiol 2012; 50: 3867-9.
15. Wingrove I, McOwan A, Nwokolo N, et al. Diagnostics within the clinic to test for gonorrhoea and chlamydia reduces the time to treatment: A service evaluation. Sex Transm Infect 2014; 90: 474.
16. van der Helm JJ, Sabajo LOA, Grunberg AW, et al. Point-of-care test for detection of urogenital Chlamydia in women shows low sensitivity. A performance evaluation study in two clinics in suriname. PLoS One. 2012; 7: E32122.
17. Mahilum-Tapay L, Laitila V, Wawrzyniak JJ, et al. New point of care Chlamydia Rapid Test-Bridging the gap between diagnosis and treatment: Performance evaluation study. BMJ 2007; 335: 1190-4.
18. Nadala E-C, Goh BT, Magbanua JP, et al. Performance evaluation of a new rapid urine test for chlamydia in men: Prospective cohort study. BMJ 2009; 339: B2655.
19. Gaydos CA, Van Der Pol B, Jett-Goheen M, et al. Performance of the Cepheid CT/ NG Xpert Rapid PCR Test for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol 2013; 51: 1666-72.
20. Sabido M, Hernandez G, Gonzalez V, et al. Clinic-based evaluation of a rapid point-of-care test for detection of Chlamydia trachomatis in specimens from sex workers in Escuintla, Guatemala. J Clin Microbiol 2009; 47: 475-6.
21. Hesse EA, Patton SA, Huppert JS, et al. Using a rapid communication approach to improve a POC Chlamydia test. IEEE Trans Biomed Eng 2011; 58: 837-40.
22. Alary M, Gbenafa-Agossa C, Aina G, et al. Evaluation of a rapid point-of-care test for the detection of gonococcal infection among female sex workers in Benin. Sex Transm Infect 2006; 82(Suppl.5): V29-32.
23. Mushanski L, Brandt K, Coffin N, et al. Comparison of the BD Viper System With XTR Technology to the Gen-Probe APTIMA COMBO 2 Assay Using the TIGRIS DTS System for the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Urine Specimens. Sex Transm Dis 2012; 39: 514-17.
24. Taylor SN, Van Der Po B, Lillis R, et al. Clinical Evaluation of the BD ProbeTec™ Chlamydia trachomatis Qx Amplified DNA Assay on the BD Viper™ System With XTR™ Technology. Sex Transm Dis 2011; 38: 603-9.
25. Suzuki K, Matsumoto T, Murakami H, et al. Evaluation of a rapid antigen detection test for Neisseria gonorrhoeae in urine sediment for diagnosis of gonococcal urethritis in males. J Infect Chemother 2004; 10: 208-11.
26. Hardwick R, Gopal Rao G, Mallinson H. Confirmation of BD ProbeTec Neisseria gonorrhoeae reactive samples by Gen-Probe APTIMA assays and culture. Sex Transm Infect 2009; 85: 24-6.
27. Van Der Pol B, Taylor SN, LeBar W, et al. Clinical Evaluation of the BD ProbeTec™ Neisseria gonorrhoeae Qx Amplified DNA Assay on the BD Viper™ System With XTR™ Technology. Sex Transm Dis 2012; 39: 147-53.
28. Schacter J, Moncada J, Liska S, et al. Nucleic acid amplification tests in the diagnosis of Chlamydial and Gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis 2008; 35: 637-42.
29. Ota KV, Tamari IE, Smieja M, et al. Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in pharyngeal and rectal specimens using the BD Probetec ET system, the Gen-Probe Aptima Combo 2 assay and culture. Sex Transm Infect 2009; 85: 182-6.
30. Pope CF, Hay P, Alexander S, et al. Positive predictive value of the Becton Dickinson VIPER system and the ProbeTec GC Q x assay, in extracted mode, for detection of Neisseria gonorrhoeae. Sex Transm Infect 2010; 86: 465-9.